DropGenie, a biotechnology company operating in Boston and Montréal, has disclosed $5 million in Seed+ financing, with BDC Thrive Venture Fund joining a round led by Skeleton Key.
The financing also includes participation from Merck Global Health Innovation Fund, CQDM, Real Ventures and Anges Québec. The company initially announced its Seed+ financing in June 2026, before disclosing the $5 million round total and BDC Thrive’s participation on October 26, 2026.
Founded in 2018, DropGenie was established by Alison Hirukawa, Hugo Sinha, Philippe Vo and Mathieu Husser. Hirukawa currently serves as co-founder and CEO, overseeing the company’s development of technologies for automated gene editing and functional biology research.
DropGenie’s automated microfluidics platform enables researchers to perform gene-editing experiments directly on primary cells obtained from patients. By miniaturizing experimental workflows, the technology reduces the quantity of biological material and reagents needed for testing.
According to the company, its platform can perform gene-editing workflows using up to 100 times fewer cells than conventional methods. The technology is designed for applications in cell therapy, functional genomics and AI-assisted drug discovery, where researchers need biological data from limited patient samples.
The newly disclosed financing will support the commercialization of DropGenie’s first product and the expansion of its customer engagement models. These include enabling laboratories to run experiments using the platform, offering research services and establishing strategic data partnerships to generate standardized biological datasets.
DropGenie is also working to extend its international reach and expand adoption among pharmaceutical companies, biotechnology developers and research organizations. The company is preparing for a broader commercial rollout in 2027.
